Want to see GENB full AI Analyst Report?
Top Page
Generate Biomedicines, Inc.
(NASDAQ:GENB)
Select Model
Select Model
Rating:49Neutral
Price Target:
$16.00
▼(-0.87% Downside)
Action:Reiterated
Date:08/27/26
The score is held down primarily by weak financial performance: very large and widening losses, accelerating cash burn, and a balance sheet burdened by deeply negative equity. Technicals provide some offset with a modestly positive trend and neutral-to-positive momentum. Valuation remains challenged due to negative earnings and no indicated dividend yield.
Positive Factors
Revenue Growth
Top-line growth indicates increasing commercial traction for the company’s platform and collaboration activities. Sustained revenue expansion could improve operating leverage over time, although the current scale remains insufficient to offset substantial research and development costs.
Negative Factors
Widening Net Losses
Losses are increasing despite revenue growth, showing that operating expenses continue to overwhelm the company’s current revenue base. Persistent, deeply negative margins could require prolonged external funding and delay the path to sustainable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Top-line growth indicates increasing commercial traction for the company’s platform and collaboration activities. Sustained revenue expansion could improve operating leverage over time, although the current scale remains insufficient to offset substantial research and development costs.
Read all positive factors
Generate Biomedicines, Inc. (GENB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.62B
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)0.49
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees312
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding128,352,430
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-1.03
Price to Sales (P/S)19.87
P/FCF Ratio-3.10
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$25.25Price Target Upside56.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Generate Biomedicines, Inc. Business Overview & Revenue Model
Company Description
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modal...
How the Company Makes Money
Generate Biomedicines primarily makes money through (1) research collaborations and strategic partnerships in which it applies its protein-design platform to discover and/or optimize therapeutic candidates for partners, and (2) payments tied to th...
Generate Biomedicines, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 13.54M | 31.89M | 20.46M |
| Gross Profit | 10.27M | 31.89M | 20.46M |
| EBITDA | -124.66M | -208.49M | -163.71M |
| Net Income | -128.70M | -203.15M | -173.77M |
Balance Sheet | |||
| Total Assets | 561.69M | 330.18M | 518.26M |
| Cash, Cash Equivalents and Short-Term Investments | 457.42M | 221.50M | 393.63M |
| Total Debt | 62.63M | 68.53M | 76.97M |
| Total Liabilities | 105.64M | 953.38M | 953.35M |
| Stockholders Equity | 456.05M | -615.97M | -434.52M |
Cash Flow | |||
| Free Cash Flow | -143.05M | -204.13M | -121.20M |
| Operating Cash Flow | -138.33M | -200.62M | -117.75M |
| Investing Cash Flow | -219.12M | 116.77M | -57.73M |
| Financing Cash Flow | 370.81M | 28.06M | 91.33M |
Generate Biomedicines, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $1.65B | -11.53 | -59.21% | ― | -62.28% | 15.36% | |
56 Neutral | $4.05B | -22.67 | -17.49% | ― | 101.28% | 2.49% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | $1.96B | -14.51 | -72.07% | ― | -69.78% | -106.07% | |
51 Neutral | $1.91B | -3.36 | -50.41% | ― | -15.08% | 41.98% | |
49 Neutral | $2.62B | -15.23 | -26.51% | ― | ― | ― |
* General Sector Average
GENB
Generate Biomedicines, Inc.
16.14
3.49
27.59%
ZYME
Zymeworks
29.31
14.38
96.28%
ABCL
AbCellera Biologics
12.24
7.89
181.38%
RXRX
Recursion Pharmaceuticals
3.49
-1.40
-28.63%
ABSI
AbSci
9.22
6.67
261.57%
EIKN
Eikon Therapeutics, Inc.
11.98
-3.02
-20.13%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.